On Wednesday, Shares of Delta Air Lines, Inc. (NYSE:DAL), added 0.42% and closed at $40.32 in the last trading session. The last trading range of the stock ranges between $40.05 and $40.47. The company’s Market capitalization is $30.32 Billion with the total Outstanding Shares of 748.91 Million. SkyTeam, the global airline alliance, has introduced an online, retroactive credit tool to make it easier for frequent flyers to keep their account balances up-to-date. Already available across most of SkyTeam’s 20 members, the tool works in real-time to validate retroactive requests for eligible flights in a matter of clicks.
The new tool eliminates the need for manual processing of post-travel claims such as when a Frequent Flyer Program (FFP) number has not been reached a reservation. Customers simply log into their FFP account, enter their flight details and the system validates the request in seconds. Eligible flights are credited to their account automatically and retroactive requests can be made as little as one week after the date of travel – the shortest time frame in the industry.
“We are offering a fast, simple and seamless way to claim missing miles across the alliance for our more than 200 million frequent flyers,” said Michael Schutzbank, SkyTeam’s Director for Customer Loyalty. “Uncredited flights can make a difference when it comes to a customer’s status level or being able to claim an award ticket, but this quick and easy solution ensures our frequent flyers benefit from every mile flown.”
AbbVie Inc (NYSE:ABBV), jumped 0.62% and closed at $63.39 in the last trading session. The last trading range of the stock ranges between $63.00 and $63.75. The company’s Market capitalization is $102.86 Billion with the total Outstanding Shares of 1.63 billion. AbbVie (ABBV), a global biopharmaceutical company, recently declared that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed previous therapy with direct-acting antivirals (DAAs) in genotype 1 (GT1), counting therapy with an NS5A inhibitor and/or protease inhibitor.
The BTD is supported by positive results seen in AbbVie’s Phase 2 MAGELLAN-1 clinical study. According to the FDA, BTD is intended to expedite the development and review of therapies for serious or life threatening conditions.1
Enterprise Products Partners L.P. (NYSE:EPD), jumped 0.71% and closed at $26.90 in the last trading session. The last trading range of the stock ranges between $26.85 and $27.12. During the 52-week trading session the minimum price at which share price traded, registered at $19.00 and reached to max level of $30.10. Enterprise Products Partners L.P. (EPD) (“Enterprise”) declared recently that the board of directors of its general partner declared a boost in the quarterly cash distribution paid to partners to $0.405 per common unit, or $1.62 per unit on an annualized basis. This distribution is equal to the distribution that Enterprise’s administration had indicated in its press release dated January 4, 2016 that it would recommend to the board of Enterprise’s general partner with respect to the third quarter of 2016.
The quarterly distribution will be paid on Monday, November 7, 2016, to unitholders of record as of the close of business on Monday, October 31, 2016. This distribution, which represents a 5.2 percent increase over the distribution declared with respect to the third quarter of 2015, is the 58th distribution increase since Enterprise’s initial public offering in 1998 and the 49th successive quarterly increase.